Non-insulin Therapies for Diabetes Market (Drug Class: Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, GLP-1 Analogs, and Sodium-glucose co-transporter-2-(SGLT2) Inhibitors; and Route of Administration: Oral and Intramuscular) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
Non-insulin Therapies for Diabetes Market – Scope of Report TMR’s report on the global non-insulin therapies for diabetes market studies the past as well as the current growth trends and opportuni... もっと見る
日本語のページは自動翻訳を利用し作成しています。
SummaryNon-insulin Therapies for Diabetes Market – Scope of ReportTMR’s report on the global non-insulin therapies for diabetes market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global non-insulin therapies for diabetes market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-insulin therapies for diabetes market from 2024 to 2034. The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the non-insulin therapies for diabetes market. Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global non-insulin therapies for diabetes market. The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global non-insulin therapies for diabetes market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global non-insulin therapies for diabetes market. The report delves into the competitive landscape of the global non-insulin therapies for diabetes market. Key players operating in the global non-insulin therapies for diabetes market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global non-insulin therapies for diabetes market profiled in this report. Key Questions Answered in Global non-insulin therapies for diabetes Market Report • What is the sales/revenue generated by non-insulin therapies for diabetes across all regions during the forecast period? • What are the opportunities in the global non-insulin therapies for diabetes market? • What are the major drivers, restraints, opportunities, and threats in the market? • Which regional market is set to expand at the fastest CAGR during the forecast period? • Which segment is expected to generate the highest revenue globally in 2034? • Which segment is projected to expand at the highest CAGR during the forecast period? • What are the market positions of different companies operating in the global market? Non-insulin Therapies for Diabetes Market – Research Objectives and Research Approach The comprehensive report on the global non-insulin therapies for diabetes market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period. The report analyzes the global non-insulin therapies for diabetes market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global non-insulin therapies for diabetes market. Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Non-insulin Therapies for Diabetes Market 4. Market Overview 4.1. Introduction 4.1.1. Product Definition 4.1.2. Industry Evolution/Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Non-insulin Therapies for Diabetes Market Analysis and Forecast, 2020-2034 5. Key Insights 5.1. Pipeline Analysis 5.2. Key Product /Brand Analysis 5.3. Key Mergers & Acquisitions 5.4. COVID-19 Pandemic Impact on Industry 6. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Drug Class 6.1. Introduction & Definition 6.2. Key Findings/Developments 6.3. Market Value Forecast, by Drug Class, 2020-2034 6.3.1. Biguanides 6.3.2. Sulfonylureas 6.3.3. Thiazolidinediones 6.3.4. Alpha-Glucosidase Inhibitors 6.3.5. DPP-4 Inhibitors 6.3.6. GLP-1 Analogs 6.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors 6.4. Market Attractiveness Analysis, by Drug Class 7. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Route of Administration 7.1. Introduction & Definition 7.2. Key Findings/Developments 7.3. Market Value Forecast, by Route of Administration, 2020-2034 7.3.1. Oral 7.3.2. Intramuscular 7.4. Market Attractiveness Analysis, by Route of Administration 8. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Distribution Channel 8.1. Introduction & Definition 8.2. Key Findings/Developments 8.3. Market Value Forecast, by Distribution Channel, 2020-2034 8.3.1. Hospital Pharmacy 8.3.2. Retail Pharmacy 8.3.3. Online Pharmacy 8.4. Market Attractiveness Analysis, by Distribution Channel 9. Global Non-insulin Therapies for Diabetes Market Analysis and Forecast, by Region 9.1. Key Findings 9.2. Market Value Forecast, by Region, 2020-2034 9.2.1. North America 9.2.2. Europe 9.2.3. Asia Pacific 9.2.4. Latin America 9.2.5. Middle East & Africa 9.3. Market Attractiveness Analysis, by Region 10. North America Non-insulin Therapies for Diabetes Market Analysis and Forecast 10.1. Introduction 10.2. Key Findings 10.3. Market Value Forecast, by Drug Class, 2020-2034 10.3.1. Biguanides 10.3.2. Sulfonylureas 10.3.3. Thiazolidinediones 10.3.4. Alpha-Glucosidase Inhibitors 10.3.5. DPP-4 Inhibitors 10.3.6. GLP-1 Analogs 10.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors 10.4. Market Value Forecast, by Route of Administration, 2020-2034 10.4.1. Oral 10.4.2. Intramuscular 10.5. Market Value Forecast, by Distribution Channel, 2020-2034 10.5.1. Hospital Pharmacy 10.5.2. Retail Pharmacy 10.5.3. Online Pharmacy 10.6. Market Value Forecast, by Country, 2020-2034 10.6.1. U.S. 10.6.2. Canada 10.7. Market Attractiveness Analysis 10.7.1. By Drug Class 10.7.2. By Route of Administration 10.7.3. By Distribution Channel 10.7.4. By Country 11. Europe Non-insulin Therapies for Diabetes Market Analysis and Forecast 11.1. Introduction 11.2. Key Findings 11.3. Market Value Forecast, by Drug Class, 2020-2034 11.3.1. Biguanides 11.3.2. Sulfonylureas 11.3.3. Thiazolidinediones 11.3.4. Alpha-Glucosidase Inhibitors 11.3.5. DPP-4 Inhibitors 11.3.6. GLP-1 Analogs 11.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors 11.4. Market Value Forecast, by Route of Administration, 2020-2034 11.4.1. Oral 11.4.2. Intramuscular 11.5. Market Value Forecast, by Distribution Channel, 2020-2034 11.5.1. Hospital Pharmacy 11.5.2. Retail Pharmacy 11.5.3. Online Pharmacy 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034 11.6.1. Germany 11.6.2. U.K. 11.6.3. France 11.6.4. Italy 11.6.5. Spain 11.6.6. Rest of Europe 11.7. Market Attractiveness Analysis 11.7.1. By Drug Class 11.7.2. By Route of Administration 11.7.3. By Distribution Channel 11.7.4. By Country/Sub-region 12. Asia Pacific Non-insulin Therapies for Diabetes Market Analysis and Forecast 12.1. Introduction 12.2. Key Findings 12.3. Market Value Forecast, by Drug Class, 2020-2034 12.3.1. Biguanides 12.3.2. Sulfonylureas 12.3.3. Thiazolidinediones 12.3.4. Alpha-Glucosidase Inhibitors 12.3.5. DPP-4 Inhibitors 12.3.6. GLP-1 Analogs 12.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors 12.4. Market Value Forecast, by Route of Administration, 2020-2034 12.4.1. Oral 12.4.2. Intramuscular 12.5. Market Value Forecast, by Distribution Channel, 2020-2034 12.5.1. Hospital Pharmacy 12.5.2. Retail Pharmacy 12.5.3. Online Pharmacy 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034 12.6.1. China 12.6.2. Japan 12.6.3. India 12.6.4. Australia & New Zealand 12.6.5. Rest of Asia Pacific 12.7. Market Attractiveness Analysis 12.7.1. By Drug Class 12.7.2. By Route of Administration 12.7.3. By Distribution Channel 12.7.4. By Country/Sub-region 13. Latin America Non-insulin Therapies for Diabetes Market Analysis and Forecast 13.1. Introduction 13.2. Key Findings 13.3. Market Value Forecast, by Drug Class, 2020-2034 13.3.1. Biguanides 13.3.2. Sulfonylureas 13.3.3. Thiazolidinediones 13.3.4. Alpha-Glucosidase Inhibitors 13.3.5. DPP-4 Inhibitors 13.3.6. GLP-1 Analogs 13.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors 13.4. Market Value Forecast, by Route of Administration, 2020-2034 13.4.1. Oral 13.4.2. Intramuscular 13.5. Market Value Forecast, by Distribution Channel, 2020-2034 13.5.1. Hospital Pharmacy 13.5.2. Retail Pharmacy 13.5.3. Online Pharmacy 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034 13.6.1. Brazil 13.6.2. Mexico 13.6.3. Rest of Latin America 13.7. Market Attractiveness Analysis 13.7.1. By Drug Class 13.7.2. By Route of Administration 13.7.3. By Distribution Channel 13.7.4. By Country/Sub-region 14. Middle East & Africa Non-insulin Therapies for Diabetes Market Analysis and Forecast 14.1. Introduction 14.2. Key Findings 14.3. Market Value Forecast, by Drug Class, 2020-2034 14.3.1. Biguanides 14.3.2. Sulfonylureas 14.3.3. Thiazolidinediones 14.3.4. Alpha-Glucosidase Inhibitors 14.3.5. DPP-4 Inhibitors 14.3.6. GLP-1 Analogs 14.3.7. Sodium-glucose co-transporter-2 (SGLT2) Inhibitors 14.4. Market Value Forecast, by Route of Administration, 2020-2034 14.4.1. Oral 14.4.2. Intramuscular 14.5. Market Value Forecast, by Distribution Channel, 2020-2034 14.5.1. Hospital Pharmacy 14.5.2. Retail Pharmacy 14.5.3. Online Pharmacy 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034 14.6.1. GCC Countries 14.6.2. South Africa 14.6.3. Rest of Middle East & Africa 14.7. Market Attractiveness Analysis 14.7.1. By Drug Class 14.7.2. By Route of Administration 14.7.3. By Distribution Channel 14.7.4. By Country/Sub-region 15. Competition Landscape 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies) 15.2. Market Share Analysis, by Company (2023) 15.3. Company Profiles 15.3.1. GSK plc 15.3.1.1. Company Overview 15.3.1.2. Product Portfolio 15.3.1.3. SWOT Analysis 15.3.1.4. Financial Overview 15.3.1.5. Strategic Overview 15.3.2. Eli Lilly and Company 15.3.2.1. Company Overview 15.3.2.2. Product Portfolio 15.3.2.3. SWOT Analysis 15.3.2.4. Financial Overview 15.3.2.5. Strategic Overview 15.3.3. Sumitomo Pharma 15.3.3.1. Company Overview 15.3.3.2. Product Portfolio 15.3.3.3. SWOT Analysis 15.3.3.4. Financial Overview 15.3.3.5. Strategic Overview 15.3.4. Intarcia Therapeutics 15.3.4.1. Company Overview 15.3.4.2. Product Portfolio 15.3.4.3. SWOT Analysis 15.3.4.4. Financial Overview 15.3.4.5. Strategic Overview 15.3.5. Servier Laboratories 15.3.5.1. Company Overview 15.3.5.2. Product Portfolio 15.3.5.3. SWOT Analysis 15.3.5.4. Financial Overview 15.3.5.5. Strategic Overview 15.3.6. Pfizer Inc. 15.3.6.1. Company Overview 15.3.6.2. Product Portfolio 15.3.6.3. SWOT Analysis 15.3.6.4. Financial Overview 15.3.6.5. Strategic Overview 15.3.7. Merck & Co., Inc. 15.3.7.1. Company Overview 15.3.7.2. Product Portfolio 15.3.7.3. SWOT Analysis 15.3.7.4. Financial Overview 15.3.7.5. Strategic Overview 15.3.8. Dong-A Pharmaceutical Co., Ltd. 15.3.8.1. Company Overview 15.3.8.2. Product Portfolio 15.3.8.3. SWOT Analysis 15.3.8.4. Financial Overview 15.3.8.5. Strategic Overview 15.3.9. Luye Pharma Group 15.3.9.1. Company Overview 15.3.9.2. Product Portfolio 15.3.9.3. SWOT Analysis 15.3.9.4. Financial Overview 15.3.9.5. Strategic Overview 15.3.10. Eurofarma Laboratories SA 15.3.10.1. Company Overview 15.3.10.2. Product Portfolio 15.3.10.3. SWOT Analysis 15.3.10.4. Financial Overview 15.3.10.5. Strategic Overview
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他)の最新刊レポート
Transparency Market Research 社の最新刊レポート
本レポートと同じKEY WORD(administration)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/09/24 10:26 144.74 円 161.12 円 195.86 円 |